Seer Inc
Change company Symbol lookup
Select an option...
SEER Seer Inc
ITCI Intra-Cellular Therapies Inc
VZ Verizon Communications Inc
TISI Team Inc
PRTK Paratek Pharmaceuticals Inc
KIRY Kiewit Royalty Trust
OCAXW OCA Acquisition Equity Warrant Exp 14 Jan 2026 *W EXP 01/31/2028
ABBV Abbvie Inc
IIIN Insteel Industries Inc
KO Coca-Cola Co
Go

Company profile

Seer, Inc. is a life sciences technology company. The Company enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The Company's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.

Closing Price
$25.17
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
517,492
0

LGVN Deadline Alert: Rosen, A Leading Law Firm, Encourages Longeveron Inc. Investors to Secure Counsel Before Important Deadline Today in Securities Class Action - LGVN

10:50 am ET November 12, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - November 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents issued in connection with the Company's initial public offering conducted on or about February 12, 2021 (the "IPO" or "Offering"); and/or (2) between February 12, 2021 and August 12, 2021, both dates inclusive (the "Class Period"), of the important November 12, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Longeveron securities pursuant and/or traceable to the IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Longeveron class action, go to http://www.rosenlegal.com/cases-register-2157.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Offering documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading, and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Offering documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) Lomecel-B, a cell-based therapy product which is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young healthy adult donors, was not as effective in treating aging frailty as defendants had led investors to believe; (2) accordingly, Lomecel-B's clinical and commercial prospects with respect to aging frailty were overstated; (3) as a result of all the foregoing, Longeveron's financial and business prospects were also overstated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Longeveron class action, go to http://www.rosenlegal.com/cases-register-2157.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103263

comtex tracking

COMTEX_396792790/2523/2021-11-12T10:50:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.